Market Trends of Global Chlamydia Infection Diagnostics Industry
This section covers the major market trends shaping the Chlamydia Infection Diagnostics Market according to our research experts:
Nucleic Acid Amplification Test (NAAT) Based Tests Dominates the Chlamydia Infection Diagnostics Market
The Nucleic Acid Amplification Test (NAAT) is found to be the most recommended method. It is a molecular test that detects DNA, the genetic material of chlamydia trachomatis. The NAAT is thus used to detect chlamydia trachomatis RNA or DNA in biological samples to diagnose and monitor the chlamydia infection. The NAAT method is usually more sensitive and specific than the other chlamydia tests. It can be performed on a vaginal swab taken from women and urine from both men and women. Thus, it eliminates the requirement for a pelvic exam in women.
The increasing product approvals are expected to drive the growth of the studied segment. For instance, in March 2022, the United States Food and Drug Administration (FDA) announced that it would allow the use of the Binx Health IO CT/N assay at point-of-care settings in physician offices, community-based clinics, urgent care settings, and other end users. Product approvals increase the prominence of the market within a population as individuals become more aware and purchase various products for the diagnosis of chlamydia infection.
The high number of chlamydia infections will increase the need for NAAT testing, which will elevate the growth of the chlamydia infection. According to the WHO, in 2022, chlamydia affects about 129 million people globally.
North America is Expected to Dominate the Chlamydia Infection Diagnostics Market Over the Forecast Period
North America is found to hold a leading position in the chlamydia infection diagnostics market during the forecast period due to the high prevalence of chlamydia infection among individuals and new product developments by the key players. According to the CDC, in 2021, there were nearly 1.6 million cases of chlamydia reported in the United States. According to America's Health Rankings, in 2021, in New Mexico, chlamydia cases (per 100,000 population) were around 576.3.
Additionally, the increasing product approvals are expected to drive the growth of the market in this region. In August 2021, Visby Medical received the 510 (k) clearance and was granted a waiver under the clinical laboratory improvement amendments of 1988 from the United States Food and Drug Administration to market its fast PCR diagnostic test for the multiplexed detection of chlamydia. Similarly, in May 2022, Abbott received FDA clearance for its Alinity m STI assay. The Alinity m STI for Chlamydia requires one swab sample or a urine sample collected by a clinician or patient in a healthcare setting.
